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Introduction
Tumor cells have acquired several ways to escape from 
host immunity in the tumor microenvironment, called 
cancer immune escape via cancer immunoediting process 
[1]. During the past two decades, several studies of cancer 
immune escape revealed that one of the most important 
components of the underlying mechanism is an immuno-
suppressive co-signal (immune checkpoint) mediated by 
programmed cell death-1 (PD-1)/PD-1 ligand 1 (PD-L1) in 
the tumor microenvironment.
PD-1 was discovered by Tasuku Honjo and colleagues 
at Kyoto University in 1992 [2]. PD-1 expressed on T cells 
negatively regulates their antitumor effect [3–5]. PD-L1 
engages with PD-1 to inhibit proliferation and cytokine 
production by T cells [6, 7]. Several studies showed that 
under normal physiological conditions, PD-L1 is expressed 
in human tonsil, placental syncytiotrophoblast, monocyte, 
and lung, where it is involved in immune tolerance [8, 
9]. Several preclinical reports also showed that inhibition 
of the interaction between PD-1 and PD-L1 enhances the 
T-cell response and mediates antitumor activity [3–5, 10]. 
Additionally, PD-L1 is expressed on various human can-
cers, including urothelial cancers, gastrointestinal cancers, 
lung cancer, breast cancer, melanoma, and ovarian cancer, 
as well as on tumor-infiltrating immune cells in the tumor 
microenvironment [8, 9, 11–18]. Therefore, to provide 
proof of principle that the PD-1/PD-L1 blockade is effec-
tive against cancer, efforts were made to develop PD-1 
inhibitors (anti-PD-1 or anti-PD-L1 antibody) for the treat-
ment of human cancers (Fig. 1). The clinical trials per-
formed to date have been highly successful.
In this review, we summarize recent clinical applications 
of PD-1/PD-L1 blockade in cancer treatment, as well as 
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discuss some pertinent perspectives and issues leading to 
further effective clinical application of PD-1 inhibitors to 
various malignant tumors in the near future.
Clinical applications of PD‑1 inhibitors in cancer
In light of fundamental research, clinical studies using 
PD-1 pathway inhibitors against treatment-resistant solid 
tumors were initiated in the United States in 2006 [19]. 
To date, at least 200 such clinical studies have been car-
ried out using nine types of antibody in at least 20 types 
of cancer, including both solid and hematological tumors; 
the total number of subjects worldwide is more than 20,000 
(Table 1).
In 2010, the first phase I clinical trial of an anti-PD-1 
antibody, nivolumab, was conducted in 39 patients with 
treatment-refractory solid tumors such as advanced 
melanoma, non-small cell lung cancer (NSCLC), renal 
cell carcinoma (RCC), prostate cancer, and colorectal 
Fig. 1  Programmed death 
(PD)-1 inhibitors in cancer. 
PD-1 inhibitors (anti-PD-1 anti-
body and anti-PD-L1 antibody) 
block PD-1/PD-L1 signaling 
and induce anti-tumor immune 
reactivation at two checkpoints: 
cognitive phase (lymph node) 
and effector phase (tumor 
microenvironment). αPD-1 Ab 
anti–PD-1 antibody, αPD-L1 Ab 
anti–PD-L1 antibody
Table 1  Programmed death (PD)-1 inhibitors (anti-PD-1 antibodies and anti-PD-L1 antibodies) in clinical testing
1  Melanoma: approved in USA, EU, and Japan
2  Lung cancer: squamous cell lung cancer in USA an EU; non small lung cancer in Japan
3  Melanoma: approved in USA, EU
4  Lung cancer: PD-L1+ non small lung cancer in USA
Target Agent IgG class Company Approved
PD-1 Nivolumab (Opdivo®, BMS-936558, MDX1106) Human IgG4 Bristol-Meyers Squibb/Ono Melanoma1
Lung cancer2
Pembrolizumab (Keytruda® MK-3475, lambrolizumab) Humanized IgG4 Merck Melanoma3
Lung cancer4
Pidilizumab (CT-011) Humanized IgG1k Cure Tech
AMP-224 PD-L2 IgG2a fusion protein Amplimmune/GlaxoSmith Klein
AMP-514 (MEDI0680) PD-L2 fusion protein Amplimmune/GlaxoSmith Klein
PD-L1 BMS-936559 (MDX1105) Human IgG4 Bristol-Meyers Squibb
Atezolizumab (MPDL3280A) Human IgG1k Roche/Genentech
Durvalumab (MEDI4736) Human IgG1k MedImmune/AstraZeneca
Avelumab (MSB0010718C) Human IgG1 Merck Serono/Pfizer
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cancer (CRC). The response rate (RR) was 7.7 %, includ-
ing one durable complete response in CRC and two partial 
responses in melanoma and RCC. Only one serious adverse 
event (inflammatory colitis) was observed, so nivolumab 
was considered to be well tolerated [19].
Subsequently, in 2012, a phase I study of nivolumab was 
carried out in a total of 296 patients with NSCLC, mela-
noma, or RCC; the mean RR values were 18 %, 28 %, and 
27 %, respectively. The most frequent adverse effects (AEs) 
were rash, diarrhea, and itching (in 12 %, 11 %, and 9 % of 
subjects, respectively); AEs that occurred in ≥1 % of sub-
jects at grade 3 or 4 were diarrhea, hepatic dysfunction, and 
pneumonia. In particular, three subjects died of pneumonia; 
consequently, a cautionary note about immunological side 
reactions has been reported [20]. In addition, in a follow-
up study, durable antitumor responses were observed, with 
overall survival (OS) of 9.9, 22.4, and 16.8 months for 
patients with NSCLC, RCC, and melanoma, respectively 
[21]. These studies constituted a turning point in the expan-
sion of clinical applications of PD-1 inhibitors, and their 
results were reported in important publications that made 
major contributions to the ongoing rapid progress with 
these agents. Representative clinical trials in different types 
of cancer are summarized here.
Melanoma
Representative phase III clinical trials with anti-PD-1 
antibodies, nivolumab and pembrolizumab, in patients 
with melanoma have led to the separate approval of both 
drugs. The first phase III trial with nivolumab as a first-
line therapy was conducted in 418 treatment-free patients 
with metastatic melanoma lacking a mutation in BRAF. 
Patients were randomized to receive either nivolumab or 
chemotherapy with dacarbazine. The overall survival rate 
at 1 year was 73 % for the nivolumab patients versus 42 % 
in dacarbazine. Similarly, median progression-free survival 
was 5.1 months in the nivolumab group versus 2.2 months 
in the dacarbazine group. The objective response rate was 
40 % in the nivolumab group as compared with 14 % in the 
dacarbazine group [22]. The second randomized phase III 
trial compared nivolumab to chemotherapy (dacarbazine or 
carboplatin/paclitaxel) in 405 patients with advanced meta-
static melanoma [23]. In contrast to the previous trial, these 
patients had all been previously treated with ipilimumab, 
and a minority had also received a BRAF inhibitor. ORR 
was threefold higher in the nivolumab group than in the 
chemotherapy group (32 % vs. 11 %).
In another randomized phase III trial, 834 patients were 
with advanced melanoma were divided equally among three 
groups: pembrolizumab every 2 weeks, pembrolizumab 
every 3 weeks, or ipilimumab every 3 weeks. The estimated 
6-month progression-free survival rates were 47 %, 46.4 %, 
and 26.5 %, respectively, and the estimated overall 1-year 
survival rates were 74 %, 68 %, and 58 %, respectively. The 
response rate was improved with pembrolizumab adminis-
tered every 2 weeks (33.7 %) and every 3 weeks (32.9 %), 
as compared with ipilimumab (11.9 %) [24].
In 2014, the U.S. Food and Drug Administration (FDA) 
approved nivolumab and pembrolizumab for the treatment 
of advanced melanoma (both are limited to be approved for 
melanoma refractory to ipilimumab and with BRAF inhibi-
tors, if the tumor harbors a BRAF mutation). Later, in 2015, 
the FDA additionally expanded an approval of nivolumab 
with BRAF wild-type and pembrolizumab for first treat-
ment of unresectable or metastatic melanoma, each.
Similar to anti-PD-1 antibodies, anti-PD-L1 antibodies 
in phase I clinical trials for melanoma have shown prom-
ising antitumor activity. The first phase I trial of an anti-
PD-L1 antibody, BMS-936559, yielded a RR of 17 % in 
52 patients with advanced melanoma [25]. Other anti-PD-
L1 antibodies, atezolizumab and durvalumab, in ongo-
ing phase I trials have also exhibited clinical activities in 
patients with NSCLC. The RR values of these antibodies 
and the sample sizes of the respective studies are as fol-
lows: atezolizumab, 30 % (n = 43) [26]; durvalumab, 13 % 
(n = 8) [27].
Lung cancer
Representative phase II or III clinical trials with anti-PD-1 
antibodies, nivolumab and pembrolizumab, in patients with 
non-small cell lung cancer (NSCLC) are described here. A 
phase II single-arm trial of nivolumab in 117 patients with 
advanced refractory squamous NSCLC yielded an RR of 
14.5 %; median duration of response had not been reached 
at the time of analysis. Although the RR was relatively low, 
there is currently no standard of care in this third-line set-
ting. Nivolumab has also exhibited promising effects as a 
second-line treatment for squamous NSCLC [28].
In a randomized phase III trial comparing nivolumab 
(n = 131) to docetaxel (n = 129) in patients with squamous 
NSCLC who had disease recurrence after one prior plati-
num-containing regimen, the median OS was 9.2 months 
in the nivolumab group versus 6.0 months in the docetaxel 
group. At 1 year, the overall survival rate was 42 % with 
nivolumab versus 24 % with docetaxel. The risk of death 
was 41 % lower with nivolumab than with docetaxel 
(HR, 0.59; P < 0.001); the response rate was 20 % with 
nivolumab versus 9 % with docetaxel (P = 0.008), and the 
median progression-free survival (PFS) was 3.5 months 
with nivolumab versus 2.8 months with docetaxel (HR, 
0.62; P < 0.001) [29]. Based on these interim data, in 2014 
the FDA expanded the approval of nivolumab to include 
squamous NSCLC with disease recurrence after one prior 
platinum-containing regimen.
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In a randomized phase III trial comparing nivolumab 
(n = 292) to docetaxel (n = 290) in non-squamous NSCLC 
after failure of platinum-doublet chemotherapy, OS was 
12.2 months in the nivolumab group versus 9.4 months 
in the docetaxel group. At 1 year, the overall survival rate 
was 51 % with nivolumab versus 39 % with docetaxel [30]. 
Based on these data, in late 2015 the FDA significantly 
expanded the approval of nivolumab to previously treated 
metastatic NSCLC. Additionally, in the first-line setting, a 
randomized phase III trial is currently underway to com-
pare nivolumab to investigator’s choice chemotherapy in 
patients with previously treated or untreated NSCLC whose 
tumors express PD-L1 [31].
Four anti-PD-L1 antibodies in the early phase of clini-
cal trials have also demonstrated clinical activity in patients 
with NSCLC. The RR values of these antibodies and the 
sample sizes of the respective studies are as follows: BMS-
936559, 10 % (n = 49) [25]; durvalumab, 16 % (n = 58) 
[32]; atezolizumab, 21 % (n = 53) [27]; avelumab, 12 % 
(n = 184) [33].
Renal cell carcinoma
In a phase II clinical trial of nivolumab in 168 patients 
with metastatic renal cell carcinoma (RCC) patients who 
had previously received vascular endothelial growth factor 
(VEGF) pathway inhibitors, RR was 21 % [34]. In a ran-
domized phase III trial of nivolumab in 821 patients with 
advanced clear cell RCC, the median OS was 25.0 months 
with nivolumab and 19.6 months with everolimus. RR was 
higher with nivolumab than with everolimus (25% vs. 5 %), 
whereas the median PFS was 4.6 months with nivolumab 
and 4.4 months with everolimus [35]. Based on these data, 
in late 2015 the FDA approved nivolumab for RCC patients 
who had received previous treatment with antiangiogenic 
therapy in late 2015.
Anti-PD-L1 antibodies in phase I clinical trials for RCC 
have also demonstrated clinical activity in patients with 
RCC. The RR values of these antibodies and the sample 
sizes of the respective studies are as follows: BMS-936559, 
12 % (n = 17) [25] and atezolizumab, 14 % (n = 56) [27] 
in patients with RCC.
Ovarian cancer
Based on our clinical studies of cancer immune escape in 
ovarian cancer [14, 36, 37], we conducted the first princi-
pal investigator-initiated two-cohort (1 or 3 mg/kg, n = 10 
each), phase II clinical trial of nivolumab in 20 patients with 
platinum-resistant recurrent ovarian cancer [38]. The trial 
was conducted in collaboration with Professor Honjo, who 
discovered the PD-1 gene [1]. RR at 3 mg/kg was 20 %, 
including 2 cases of a durable complete response (CR). 
Among all 20 patients, RR was 15 % and DCR was 45 %; 
median PFS and OS were 3.5 and 20.0 months, respectively 
[39]. In our ongoing follow-up study subsequent to this 
trial, a durable antitumor response with nivolumab has been 
observed in 2 patients with a CR for more than 1 year [40]. 
After completing the 1-year nivolumab treatment accord-
ing to our study design, these 2 patients have each survived 
without any disease progression for more than 1 year, with 
no adjuvant antitumor treatment [41].
Later, the interim results became available from two 
other phase Ib clinical trials with anti-PD-1 antibody [25] 
and anti-PD-L1 antibody (avelumab). In the trial of pem-
brolizumab in 26 patients with PD-L1+ advanced ovarian 
cancer, RR was 11.5 % [42]. In the trial of avelumab in 75 
patients with recurrent or refractory ovarian cancer, RR 
was 10.7 % [43].
Head and neck cancer
The anti-PD-1 antibody pembrolizumab exhibited antitu-
mor activity in patients with refractory squamous cell carci-
noma of the head and neck cancer (SCCHN), whose tumors 
expressed ≥1 % PD-L1 (RR = 20 % in 56 patients) [44]. 
Anti-PD-L1 antibodies in phase I clinical trials for SCCHN 
have also exhibited clinical activity. The RR values of these 
antibodies and the sample sizes of the respective studies are 
as follows: durvalumab, 14 % (n = 22) [45]; atezolizumab, 
17 % (n = 6) [27].
Bladder cancer
In a phase I clinical trial of pembrolizumab in 29 patients 
with advanced bladder cancer patients whose tumors 
expressed ≥1 % PD-L1, RR was 24 %, including three 
cases of CR [46]. Another anti-PD-L1 antibody, atezoli-
zumab, yielded a RR of 26 % in 68 patients with advanced 
bladder cancer [47]. Based on these findings, in 2014 the 
FDA set the ‘Breakthrough’ designation for the clinical 
development of atezolizumab for treatment of advanced 
bladder cancer.
Gastric cancer
In a phase I trial of pembrolizumab in 39 patients with 
advanced gastric cancer, RR was 22 %. Median time to 
response was 8 weeks, with a median response duration of 
24 weeks. The 6-month PFS and OS rates were 24 % and 
69 %, respectively [48].
Colon cancer
In a phase II clinical trial of pembrolizumab in 50 patients 
with colon cancer, RR was higher in the mismatch 
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repair-deficient group (n = 25) than in the mismatch repair-
proficient group (n = 25), 62 % versus 0 % [49] (see “Clin-
ical perspectives and issues of PD-1 inhibitors” for details).
Esophageal cancer
In a phase I study of pembrolizumab in 22 patients with 
esophageal cancer, RR was 23 %, including 3 (11 %) cases 
of CR [50].
Hepatocellular cancer
In a phase I/II trial of nivolumab in 42 patients with hepa-
tocellular carcinoma, CR was reported in 2 patients (5 %) 
and PR in 7 patients (18 %) for an overall objective RR 
of 23 %. Overall survival (OS) rate at 6 months was 72 % 
[51].
Breast cancer
In a phase 1b trial of pembrolizumab in 25 patients with 
advanced triple-negative breast cancer (TNBC) whose 
tumors expressed ≥1 % of PD-L1, RR was 12 % [52]. A 
phase Ia study of the anti-PD-L1 antibody atezolizumab in 
27 patients with metastatic TNBC yielded a RR of 19 %, 
including 1 CR and 4 PRs [53].
Hematological malignancies
Nivolumab has shown dramatic antitumor effects in 
patients with relapsed or refractory Hodgkin’s lymphoma 
(HL) (n = 23), with a RR of 87 % and a DCR of 100 %, 
including CR in 20 % of patients [54].
Pembrolizumab also yielded a RR of 53 % in 15 patients 
with pre-treated HL, including CR in 20 % of patients [55]. 
In a phase I trial of nivolumab in patients with non-HL, 
diffuse follicular lymphoma (n = 10) or large B-cell lym-
phoma (n = 11), RR values were 40 % and 36 %, respec-
tively [56].
Clinical perspectives and issues of PD‑1 inhibitors
The accumulated data from clinical trials for solid tumors 
revealed that the antitumor response rate of PD-1 inhibi-
tors seems not so high. Therefore, there is an urgent need 
to resolve several issues related to PD-1 inhibitors (Fig. 3). 
First, to enhance the antitumor effect of PD-1 inhibitors, we 
have to find the best combination therapy with other antitu-
mor therapy such as chemotherapy, targeted therapy, radio-
therapy, or other immunotherapy. Second, because PD-1 
inhibitors are very expensive, it is necessary to identify 
predictive biomarkers that allow selection of appropriate 
patients. Third, we must learn how to manage severe immu-
nological side effects. Last, we have to investigate the most 
valuable application of PD-1 inhibitors.
Development of effective combination therapies
Clinical trials of combination treatments incorporating 
PD-1 inhibitors with conventional chemotherapies [57], 
molecular targeted drugs such as PARP inhibitors (olapa-
rib and cediranib) for solid tumors [58], or multi-kinase 
inhibitor (sunitinib) for RCC [59], focal radiation therapy, 
and cancer immunomodulators are now underway. In par-
ticular, therapy using double-checkpoint inhibitors in 
combination with nivolumab and ipilimumab for the treat-
ment of advanced melanoma led to longer PFS than either 
agent alone [60]. However, the frequency of grade 3 or 4 
immune-related AEs was also amplified to more than 50 %. 
Similar combinations are now being clinically applied to 
diverse cancer types, including RCC [61], NSCLC [62], or 
ovarian cancer [63].
Next-generation clinical trials are also underway for 
PD-1 inhibitors in combination with other immune modu-
lators such as anti-lymphocyte activation gene 3 (LAG3) 
antibody for solid tumors [64], anti-killer inhibitory recep-
tor (KIR) antibody, lirilumab, for solid tumors [65], anti-
OX40 agonistic antibody, MEDI6383, for solid tumors 
[66], anti-4-1BB agonistic antibody, urelumab, for solid 
tumors and B-cell non-Hodgkin lymphoma [67], and GM-
CSF-producing and CD40L-expressing bystander cell line 
(GM.CD40L) vaccine for NSCLC [68].
Identification of biomarkers
The identification of predictive biomarkers of PD-1 inhibi-
tors is a crucial next step for advancing the applications of 
these drugs. Potential predictive biomarkers of antitumor 
response to PD-1 inhibitors can be considered in either 
tumor cell-related factors or host immunological factors. 
Recent studies identified several candidate biomarkers: 
expression of PD-L1 in tumor cells and tumor-infiltrating 
lymphocytes, frequencies of mutations in tumor cells, and 
diversity of tumor antigen-specific T cells (T-cell reper-
toire). All these candidates are regarded as viable prospects, 
although some concerns are associated with each of them.
PD-L1 and TILs
Since the first clinical trial of nivolumab in 2010 [19], sev-
eral reports of clinical trials of PD-1 inhibitors have shown 
that the therapeutic efficacy of PD-1 inhibitors is modestly 
correlated with PD-L1 expression in tumors [20, 22, 27, 47, 
48, 69, 70]. In addition, with respect to tumors such as mel-
anoma and bladder cancer, not only tumor cells, but also 
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the number of infiltrating T cells and the proportion of T 
cells positive for PD-L1 or PD-1 expression, can be used as 
indices of therapeutic efficacy [27, 47, 71]. In other words, 
the effects of PD-1 pathway-inhibiting drugs occur when 
tumor cells and immune cells are present at a particular 
locus and the cancer-immunosuppressive state mediated by 
the PD-1 pathway has been established. In future, in addi-
tion to follow-up studies, diagnostic-grade evaluation and 
accuracy control of PD-L1 expression will also be required. 
Therefore, there is a need to establish clearer and more 
accurate analysis methods [72].
On the other hand, it is probable that PD-L1 expres-
sion by tumors will change during treatment in response 
to the immune state and the administration of therapeutic 
drugs [27, 73–75]. Therefore, it is necessary to investigate 
the influence of parameters such as the timing and locus of 
sample collection by biopsies and surgery; whether sam-
ples are embedded in paraffin or frozen; and evaluation 
methods such as immunostaining, quantitative polymerase 
chain reaction (PCR), and Western blotting. In addition, in 
cases of tumors within an abdominal cavity, whether pri-
mary, secondary, or metastatic, it is often difficult to carry 
out biopsies from the body surface. Consequently, various 
issues must be investigated and analyzed, such as the dif-
ferent sampling modes needed to collect different types of 
tumor tissue.
Furthermore, since in the case of nivolumab for Hodg-
kin’s lymphoma patients, the response rate was 87 % 
and the disease-control rate was 100 % [54], biomarkers 
per se are not useful in such a type of tumor for which 
efficacy has been demonstrated. On the other hand, in 
a phase I/II nivolumab study in SCLC patients [76], a 
phase III nivolumab study in lung squamous cell carci-
noma patients [29], and a phase III study of nivolumab 
plus ipilimumab combination therapy in melanoma 
patients [60], no significant correlations were observed 
between PD-L1 expression and therapeutic efficacy. 
However, in the nivolumab plus ipilimumab combina-
tion therapy study, a subanalysis did reveal correlations 
between PD-L1 expression and therapeutic efficacy in 
the nivolumab monotherapy group. Therefore, it might 
be useful to establish a paradigm for therapy selection in 
which nivolumab monotherapy is used when a tumor is 
positive for PD-L1 expression, but combination therapy 
is used when it is negative. In all these studies, thera-
peutic efficacy was observed even with PD-L1-negative 
patients, and it is therefore probably inappropriate to 
select patients solely on the basis of whether they express 
PD-L1 [60]. Thus, there is a demand for immunologically 
individualized treatment methods that can be selected 
accurately, with consideration given to other factors such 
as cancer type and histological subtype.
Relationship between PD-1 signal and genomic mutation
Rapid progress has also been made in reverse-translational 
research using specimens from patients who received 
immune checkpoint inhibitors. In addition, recent progress 
in genomic analysis using next-generation sequencing 
techniques has enabled comprehensive detection of muta-
tions in cancer tissue. According to The Cancer Genome 
Atlas, which covers 7042 tumor samples from 30 cancer 
types, the frequency of somatic gene mutations is highest 
in melanoma, followed by lung squamous cell carcinoma, 
lung adenocarcinoma, bladder cancer, stomach cancer, 
and esophageal adenocarcinoma [77]. PD-1-inhibitors are 
expected to be therapeutically effective in cancer types 
with high somatic gene mutation frequencies [78, 79]. In 
other words, cancer types with numerous mutations neces-
sarily also express numerous mutant cancer antigens, and 
immunosuppression mediated by the PD-1 pathway occurs 
in the presence of numerous T cells that specifically recog-
nize those mutant antigens. Thus, PD-1 pathway inhibitors 
represent a promising class of drugs for use in such cases 
(Fig. 2). This position supports the findings of fundamental 
research using a mouse model that demonstrated the exist-
ence of mutant cancer antigen-specific T cells, as well as 
reactivation of these cells by anti-PD-1 antibodies and anti-
CTLA-4 antibodies (CTLA-4 is a receptor for the same 
immunosuppressive signals as PD-1) [80].
Snyder et al. performed whole-exome sequencing of 
tumors from 64 melanoma patients who had been treated 
with the anti-CTLA-4 antibody ipilimumab or tremeli-
mumab. The results revealed durable clinical efficacy in 
11 subjects, and the mutation levels in these patients were 
significantly elevated [81]. Because neither of these factors 
is sufficient as a predictive marker for treatment, genome-
wide somatic cell neo-epitope analysis and HLA analysis 
were carried out, resulting in identification of a neo-epitope 
candidate that is specifically expressed in tumors against 
which anti-CTLA-4 antibodies are therapeutically effec-
tive. This neo-epitope was validated in a dataset compris-
ing 39 melanoma patients. In addition, the neo-epitope 
activated T cells derived from patients who received ipili-
mumab, demonstrating the usefulness of mutation analysis 
by whole-exome sequencing, as well as neo-epitope analy-
sis, in predicting the therapeutic efficacy of anti-CTLA-4 
antibodies.
In addition, Rizvi et al. carried out whole-exome 
sequence analysis of tumors in NSCLC patients treated 
with the anti-PD-1 antibody pembrolizumab. The results 
revealed that when numerous non-synonymous mutations 
were present, there were correlations between response to 
treatment, durable clinical benefit (i.e., partial response or 
stable disease for at least 6 months), and recurrence-free 
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survival rate [82]. Similarly, correlations were observed 
between therapeutic efficacy and a set of genes that is 
upregulated in smokers, neo-antigen count, and mutations 
in the DNA-repair pathway, all of which are linked to the 
mutation level. Furthermore, some studies have described 
patients who exhibit neo-antigen-specific T-cell immune 
responses that increase with tumor contraction upon treat-
ment with pembrolizumab. Therefore, it is possible that the 
efficacy of pembrolizumab treatment against lung cancer is 
determined by the genomic landscape of the cancer.
In addition, Le et al. found that in a phase II treme-
limumab study carried out previously in CRC patients, 
1 of 47 subjects exhibited a partial response. In addi-
tion, in a phase I study in which the anti-PD-L1 antibody 
MPDL3280A was administered to 20 subjects, 1 CRC 
patient with deletion of a mismatch repair (MMR) gene 
exhibited a partial response [49]. Therefore, the anti-
PD-1 antibody pembrolizumab was administered to three 
cohorts, A, B, and C, respectively, comprising 25 CRC 
patients with MMR deletion, 25 CRC patients with normal 
MMR, and 21 patients with cancers other than CRC with 
MMR deletion. The therapeutic efficacy was very high in 
the CRC patients with MMR deletion, with a response rate 
of 62 % and a disease-control rate of 92 %. By contrast, in 
the 25 CRC patients with normal MMR, the efficacy was 
very low, with a response rate of 0 % and a disease-con-
trol rate of 16 %. Furthermore, in the subjects with non-
CRC cancers with MMR deletions, the response rate and 
disease-control rate were 60 % and 70 %, respectively, sug-
gesting the possibility that MMR deletion is a predictive 
factor for the therapeutic efficacy of anti-PD-1 antibody, 
pembrolizumab.
In the manner already described, a search for biomarkers 
was recently carried out via comprehensive mutation analy-
sis of the cancer genome using next-generation sequencing 
technology. This approach is termed mutanome analysis 
when it involves genome-wide mutation analysis of cancer 
cells, and immunome analysis when it involves a compre-
hensive exploratory analysis related to tumor immunology; 
the latter includes diversity analysis of a T-cell repertoire, 
microarray analysis, and protein analysis. By making exten-
sive use of these techniques, high-throughput extraction of 
markers can be carried out more effectively, and rapid pro-
gress is being made in verification techniques for validation 
studies even in the field of cancer immunology (Fig. 2).
Integrating several biomarkers in an algorithm
As already mentioned, several candidates for predic-
tive biomarkers were recently identified. Further study is 
Fig. 2  Relationship between PD-1 signal and genomic mutation. 
Mutated neo-antigens are expressed on the surface of a cancer cell 
in response to genomic mutation and amplification of a cancer cell. 
Recognition of a neo-antigen as a foreign body by an antigen-present-
ing cell (APC) induces a T-cell response, and consequently the acti-
vated T cell releases interferon (IFN)-γ. A cancer cell that is exposed 
to IFN-γ expresses PD-L1, thereby establishing an acquired immune 
resistance. In this type of tumor microenvironment, a PD-1 pathway 
inhibitor should be effective; thus, genome-wide mutation analy-
sis (i.e., mutanome analysis) of cancer cells using next-generation 
sequencing technology and diversity analysis of the T-cell repertoire 
(i.e., the immunome) have attracted attention as strategies for identifi-
cation of predictive biomarkers. APC antigen-presenting cell
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necessary to improve our understanding of their clinical 
significance, however, as the best strategy may involve 
more than one biomarker. Therefore, biomarker combi-
nations and algorithms may be required. For example, it 
will be important to determine whether it is necessary to 
use combinations of biomarkers such as PD-L1+ tumor 
cells, PD-L1+ and PD-1+ tumor-infiltrating lymphocytes, 
frequencies of neo-antigens and tumor mutations, and the 
diversity of the T-cell repertoire. Additionally, more candi-
date predictive biomarkers will be identified in the future. 
Therefore, the development of useful algorithms or com-
binations of these biomarkers is a high priority for future 
work (Fig. 3).
Immunological side effects
Common drug-related adverse events (AEs) of both anti-
PD-1 and anti-PD-L1 antibodies include fatigue, rash, diar-
rhea, pruritus, decreased appetite, arthralgia, and nausea 
[20, 22, 23, 29, 83–87]. In particular, immune-related AEs 
(irAEs) such as dermatitis, colitis, hepatitis, vitiligo, and 
thyroiditis have been reported, and about 10 % of patients 
develop grade 3 or 4 irAEs. Rare (<10 %) but life-threat-
ening irAEs include pneumonitis (including acute inter-
stitial pneumonia/acute respiratory distress syndrome), 
colitis with gastrointestinal perforation, infusion reaction 
and anaphylactic shock, type 1 diabetes, severe skin reac-
tions, immune thrombocytopenia, neutropenia and sepsis 
risk after corticosteroid therapy, encephalopathy and neu-
rological sequelae, Guillain–Barré syndrome, myelitis and 
motor sequelae, myocarditis and cardiac insufficiency, and 
acute adrenal insufficiency and nephritis [83, 84]. In the 
first phase II trial of nivolumab, grade 1 or 2 pneumonitis 
in 6 of 296 patients was reversible upon discontinuation of 
treatment and administration of glucocorticoid, but 3 of 296 
patients (1 %) died of pneumonitis. On the basis of these 
findings, guidelines and specific algorithms for identifica-
tion, early intervention, and management of irAEs have 
been developed [20, 25]. In the clinical setting, if severe 
irAEs occur, clinicians should perform a timely evalua-
tion to confirm the diagnosis, and if necessary, admit the 
patient to the hospital and treat with intravenous corticos-
teroids without hesitation. Moreover, if corticosteroids are 
not effective, clinicians should consider using additional 
immunosuppressive drugs such as anti-tumor necrosis fac-
tor (TNF) antibody (i.e., infliximab) [83].
Although irAEs can develop at any time, the major-
ity of immune toxicities of nivolumab occur within the 
first 4 months [84, 85]. The median time to onset of irAEs 
tends to differ depending on the type of toxicity, and can be 
roughly classified as early (<2 months) or late (>2 months). 
Early toxicities include skin (5 weeks), gastrointestinal 
(7 weeks), and hepatic (7 weeks), whereas late toxicities 
include pulmonary (9 weeks), endocrine (10 weeks), and 
renal (15 weeks). However, clinicians should keep in mind 
that all types of irAEs can occur at any time [84, 87–89].
Finally, we, as gynecologists, believe that we should 
investigate the gender differences in frequency and sever-
ity of side effects and evaluate the risk of infertility for 
younger men or women who receive PD-1 inhibitors. 
Fig. 3  Identification of the best biomarker strategy. A combination 
or algorithm of biomarkers may be needed. For example, it is impor-
tant to understand whether it will be necessary to use a combination 
of biomarkers, e.g., PD-L1+ tumor cells, PD-L1+, and/or PD-1+ 
tumor-infiltrating lymphocytes, frequencies of neo-antigens and 
tumor mutations, and diversity of the T-cell repertoire. Additionally, 
more candidate predictive biomarkers will be identified in the future. 
Therefore, development of an algorithm or combination of these bio-
markers should be a high priority for future work
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Currently, very little is known about the influence of PD-1 
inhibitors on human fertility or pregnancy (Fig. 3). The 
drug package insert of nivolumab [86] describes embryofe-
tal toxicity in the cynomolgus monkey and advises females 
with reproductive potential to use effective contraception 
during treatment with nivolumab and for at least 5 months 
after the last dose.
The value of PD‑1 inhibitors
On the other hand, the American Society of Clinical 
Oncology increasingly emphasizes the value of antican-
cer treatments, referring to their benefit/cost ratio [90, 91]. 
In other words, in future, for anti-cancer treatments to be 
considered excellent, evaluation of the cost (i.e., medical 
expenses) and toxicity (i.e., AEs) of each will be recom-
mended, in addition to its benefit (antitumor efficacy); fur-
thermore, it will be important to select overall treatments 
that are appropriate for the individual patient’s background 
and physical condition (Fig. 4). In this context, to judge the 
value of PD-1 pathway inhibitors, there is an urgent need 
to establish patient selection methods based on biomarkers, 
permitting prediction of the efficacy and AEs of PD-1 path-
way inhibitors.
Conclusion
More than 20 years after the discovery of PD-1 [1], several 
studies have identified the clinical efficacy of PD-1 block-
ade against a wide spectrum of solid and hematological 
malignancies, opening the door to a strategy for the treat-
ment of cancer. In addition, on the basis of reports of clini-
cal findings obtained using PD-1 inhibitors, longstanding 
theories regarding cancer immune surveillance [92] and 
cancer immunoediting, including the mechanism of cancer 
immune escape [93, 94], have recently been confirmed by 
fundamental research on tumor immunology. Nevertheless, 
a great deal of fundamental, exploratory research remains 
to be done on areas such as predictive biomarkers for ther-
apeutic efficacy and adverse drug reactions. In future, we 
anticipate that clinical studies of PD-1 inhibitors and deep 
reverse-translational programs involving molecular and 
genomic research will reveal fundamental details of PD-1/
PD-L1 signaling.
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